In8Bio Inc (INAB) Stock Price, Quote & News

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 600 6438

Website: in8bio.com

Address:

350 5th Avenue, Suite 5330, New York, United States

Picklerinthekitchen Jul. 7 at 11:05 AM

$INAB with such a low float INAB can easily dilute some shares out and raise quite enough money to continue onward and partner up as long as their trials continue to be positive.

0 · Reply

buymoremakemore Jul. 5 at 5:57 PM

$INAB TC BioPharm also focuses on gamma delta for AML. They trade on OTC. There are enough players in gamma delta T cell space that there needs to be something more special than a single Phase 2 ready oncology asset for partnerships and buyout. Especially something competitive like GBM which has increasingly impactful treatment options. Gene therapy companies too have good results for horrible diseases such as cancer and many have no investor/partner interest. Let's see how many quarters this goes with management saying a partnership is being worked on before this is under $1 again. Look at SGMO with Fabry Disease. And look at CMMB which is also low float but no partnership interest for PSC, a serious liver disease

1 · Reply

buymoremakemore Jul. 4 at 3:25 PM

$INAB This could be the next SGMO. Giving away IP for major illnesses basically for free to BP and saying partnerships are coming but have yet to.

1 · Reply

Olena Jul. 3 at 6:55 PM

$INAB any upcoming catalyst here? Besides low OS after RS and no cash on hands really

1 · Reply

DavidDayTrade Jul. 3 at 4:06 PM

$INAB LOOKS LIKE IT'S READY TO GO

0 · Reply

BiotechBonesaw Jul. 3 at 3:26 PM

$INAB $RGC Nonsense, sir! $TNXP is the next RGC. 👍 Praise be. It is hot as hell out my brother in Christ. I’m going to the pool. 🏊‍♂️

0 · Reply

Adamchristlover Jul. 3 at 3:23 PM

$INAB I think this will be the next $RGC . It will got to 50 this year.

1 · Reply

jacksparo Jul. 3 at 3:17 PM

$INAB I will keep a close eye on this for next week!!!

1 · Reply

3ARated Jul. 3 at 3:13 PM

$INAB Looking good

0 · Reply

DavidDayTrade Jul. 2 at 6:24 PM

$INAB it will come soon

0 · Reply

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Jun 2, 2025, 7:30 AM EDT - 5 weeks ago

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

May 14, 2025, 8:00 AM EDT - 7 weeks ago

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

May 12, 2025, 8:00 AM EDT - 2 months ago

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

May 7, 2025, 4:00 PM EDT - 2 months ago

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 29, 2025, 8:00 AM EDT - 2 months ago

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Apr 28, 2025, 8:00 AM EDT - 2 months ago

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

Mar 31, 2025, 8:00 AM EDT - 3 months ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

Mar 18, 2025, 8:05 AM EDT - 3 months ago

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Mar 13, 2025, 4:05 PM EDT - 4 months ago

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 3, 2025, 9:28 AM EST - 4 months ago

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Feb 26, 2025, 8:00 AM EST - 4 months ago

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 4 months ago

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 14, 2025, 9:00 AM EST - 5 months ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Feb 11, 2025, 8:00 AM EST - 5 months ago

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Dec 10, 2024, 7:00 AM EST - 7 months ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Nov 12, 2024, 4:26 PM EST - 8 months ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Sep 4, 2024, 4:01 PM EDT - 10 months ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Aug 29, 2024, 6:05 AM EDT - 11 months ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 8:05 AM EDT - 11 months ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Jun 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 13, 2024, 4:01 PM EDT - 1 year ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Jun 3, 2024, 6:05 AM EDT - 1 year ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 23, 2024, 5:00 PM EDT - 1 year ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 10:00 AM EDT - 1 year ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

May 13, 2024, 8:00 AM EDT - 1 year ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

May 9, 2024, 4:00 PM EDT - 1 year ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Apr 30, 2024, 6:05 AM EDT - 1 year ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

Apr 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 16, 2024, 4:05 PM EDT - 1 year ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 9, 2024, 4:30 PM EDT - 1 year ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Mar 14, 2024, 4:00 PM EDT - 1 year ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Mar 5, 2024, 4:30 PM EST - 1 year ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Feb 26, 2024, 8:00 AM EST - 1 year ago

IN8bio to Present at Upcoming Investor Conferences

Feb 14, 2024, 8:00 AM EST - 1 year ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Jan 4, 2024, 8:00 AM EST - 1 year ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Dec 11, 2023, 4:05 PM EST - 1 year ago

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Dec 11, 2023, 9:00 AM EST - 1 year ago

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Dec 7, 2023, 8:00 AM EST - 1 year ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Dec 5, 2023, 8:00 AM EST - 1 year ago

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

Nov 20, 2023, 7:00 AM EST - 1 year ago

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

Nov 10, 2023, 7:00 AM EST - 1 year ago

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Nov 9, 2023, 4:00 PM EST - 1 year ago

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 8:00 AM EST - 1 year ago

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Nov 3, 2023, 12:00 PM EDT - 1 year ago

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Nov 2, 2023, 9:17 AM EDT - 1 year ago

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

Nov 1, 2023, 8:00 AM EDT - 1 year ago

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

Oct 12, 2023, 8:00 AM EDT - 1 year ago

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

Sep 29, 2023, 8:00 AM EDT - 1 year ago

IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting

Picklerinthekitchen Jul. 7 at 11:05 AM

$INAB with such a low float INAB can easily dilute some shares out and raise quite enough money to continue onward and partner up as long as their trials continue to be positive.

0 · Reply

buymoremakemore Jul. 5 at 5:57 PM

1 · Reply

buymoremakemore Jul. 4 at 3:25 PM

$INAB This could be the next SGMO. Giving away IP for major illnesses basically for free to BP and saying partnerships are coming but have yet to.

1 · Reply

Olena Jul. 3 at 6:55 PM

$INAB any upcoming catalyst here? Besides low OS after RS and no cash on hands really

1 · Reply

DavidDayTrade Jul. 3 at 4:06 PM

$INAB LOOKS LIKE IT'S READY TO GO

0 · Reply

BiotechBonesaw Jul. 3 at 3:26 PM

$INAB $RGC Nonsense, sir! $TNXP is the next RGC. 👍 Praise be. It is hot as hell out my brother in Christ. I’m going to the pool. 🏊‍♂️

0 · Reply

Adamchristlover Jul. 3 at 3:23 PM

$INAB I think this will be the next $RGC . It will got to 50 this year.

1 · Reply

jacksparo Jul. 3 at 3:17 PM

$INAB I will keep a close eye on this for next week!!!

1 · Reply

3ARated Jul. 3 at 3:13 PM

$INAB Looking good

0 · Reply

DavidDayTrade Jul. 2 at 6:24 PM

$INAB it will come soon

0 · Reply

jacksparo Jul. 2 at 5:49 PM

$INAB Maybe if not this week .. Next week?! It is getting closer to some action here!!

1 · Reply

Zackpedia Jul. 1 at 10:46 PM

$INAB Exactly, hit Follow and subscribe to get my alerts on time and make money

0 · Reply

Florestan Jul. 1 at 5:37 PM

$INAB raise money and save the programs. No other choice.

0 · Reply

Golibajje Jul. 1 at 3:48 PM

$PLRX hold it strongly! Over $4+ cash.. look at also $INAB.. only 2.7m public float.. treating difficult types of brain cancer.. can run like $LYRA over 500% when they report topline data anytime from now!! $GOSS $BGLC

0 · Reply

Picklerinthekitchen Jun. 30 at 8:22 PM

$INAB hanging tight !

0 · Reply

Ulong Jun. 30 at 8:13 PM

$INAB "IN8bio, Inc. (NASDAQ:INAB) announced Monday that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires companies listed on the exchange to maintain a minimum bid price of at least $1.00 per share. The stock, currently trading at $2.13, has faced significant challenges, having declined over 90% in the past year according to InvestingPro data." ... https://www.investing.com/news/sec-filings/in8bio-regains-compliance-with-nasdaq-minimum-bid-price-requirement-93CH-4116984

2 · Reply